Phase 3 trial results bring hope for patients with IgA nephropathy
Lancet
.
2023 Sep 9;402(10405):827-829.
doi: 10.1016/S0140-6736(23)01633-1.
Epub 2023 Aug 14.
Author
Börje Haraldsson
1
Affiliation
1
Institute of Neuroscience and Physiology, University of Gothenburg, 405 30 Gothenburg, Sweden. Electronic address: borje.haraldsson@gu.se.
PMID:
37591290
DOI:
10.1016/S0140-6736(23)01633-1
No abstract available
Publication types
Clinical Trial, Phase III
Comment
MeSH terms
Glomerulonephritis, IGA* / therapy
Humans
Patients